AU2006211485B2 - Bacterial glycolipid activation of CD1d-restricted NKT cells - Google Patents

Bacterial glycolipid activation of CD1d-restricted NKT cells Download PDF

Info

Publication number
AU2006211485B2
AU2006211485B2 AU2006211485A AU2006211485A AU2006211485B2 AU 2006211485 B2 AU2006211485 B2 AU 2006211485B2 AU 2006211485 A AU2006211485 A AU 2006211485A AU 2006211485 A AU2006211485 A AU 2006211485A AU 2006211485 B2 AU2006211485 B2 AU 2006211485B2
Authority
AU
Australia
Prior art keywords
alkyl
cells
cell
nkt
pbs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006211485A
Other languages
English (en)
Other versions
AU2006211485A1 (en
Inventor
Albert Bendelac
Paul Savage
Luc Teyton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Brigham Young University
Scripps Research Institute
Original Assignee
University of Chicago
Brigham Young University
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago, Brigham Young University, Scripps Research Institute filed Critical University of Chicago
Publication of AU2006211485A1 publication Critical patent/AU2006211485A1/en
Application granted granted Critical
Publication of AU2006211485B2 publication Critical patent/AU2006211485B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006211485A 2005-01-28 2006-01-26 Bacterial glycolipid activation of CD1d-restricted NKT cells Ceased AU2006211485B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64815305P 2005-01-28 2005-01-28
US60/648,153 2005-01-28
PCT/US2006/002781 WO2006083671A2 (en) 2005-01-28 2006-01-26 Bacterial glycolipid activation of cd1d-restricted nkt cells

Publications (2)

Publication Number Publication Date
AU2006211485A1 AU2006211485A1 (en) 2006-08-10
AU2006211485B2 true AU2006211485B2 (en) 2011-04-14

Family

ID=36777772

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006211485A Ceased AU2006211485B2 (en) 2005-01-28 2006-01-26 Bacterial glycolipid activation of CD1d-restricted NKT cells

Country Status (12)

Country Link
US (1) US9295722B2 (enExample)
EP (1) EP1848813B1 (enExample)
JP (1) JP5053101B2 (enExample)
AU (1) AU2006211485B2 (enExample)
BR (1) BRPI0607299A2 (enExample)
CA (1) CA2593715C (enExample)
DK (1) DK1848813T3 (enExample)
ES (1) ES2423005T3 (enExample)
PL (1) PL1848813T3 (enExample)
PT (1) PT1848813E (enExample)
WO (1) WO2006083671A2 (enExample)
ZA (1) ZA200706208B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
WO2007118234A2 (en) 2006-04-07 2007-10-18 The Scripps Research Institute Modified -galactosyl ceramides for staining and stimulating natural killer t cells
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
WO2008128207A1 (en) * 2007-04-13 2008-10-23 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
AU2013202865B2 (en) * 2007-11-07 2015-03-19 Abivax Increase of immune response and targeting by antigens and/or drug linkage
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
EP2060252A1 (en) 2007-11-19 2009-05-20 Wittycell New formulation of galactosylceramide derivatives
BRPI0820960B8 (pt) * 2007-12-05 2021-05-25 Abivax composição, composição farmacêutica, e uso da composição
US9220767B2 (en) 2008-10-08 2015-12-29 Abivax Vaccine composition for use against influenza
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
JP6548579B2 (ja) * 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
CN115666586A (zh) * 2020-04-23 2023-01-31 加州大学评议会 通过激活iNKT细胞清除衰老细胞
KR20230119224A (ko) * 2020-12-18 2023-08-16 로레알 스핑고모나스 속 박테리아 추출물
FR3117776B1 (fr) * 2020-12-18 2024-03-08 Oreal Extrait de bactérie du genreSphingomonas
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
WO2024107463A1 (en) * 2022-11-14 2024-05-23 The Trustees Of Columbia University In The City Of New York 7dw8-5 treatment for covid-19 and other virus-induced respiratory infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018039A1 (en) * 2001-08-22 2003-03-06 Dna Informatics Inc. Pharmaceutical ingredient for medical treatment and preventing of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (enExample) 1992-07-16 1995-11-01 Kirin Brewery
ATE191916T1 (de) 1992-10-22 2000-05-15 Kirin Brewery Neues sphingolglycolipid und verwendung davon
US5780441A (en) 1993-04-15 1998-07-14 Kirin Beer Kabushiki Kaisha Sphingoglycolipid compounds and therapeutic uses thereof
CN1125449A (zh) 1993-05-14 1996-06-26 萨依特尔有限公司 作为细胞粘附抑制剂的唾液基Lex类似物
EP1520583B1 (en) 1997-04-10 2009-01-28 Kyowa Hakko Kirin Co., Ltd. NKT cell-activating agents containing alpha-glycosylceramides
EP1011719A1 (en) * 1997-09-12 2000-06-28 Brigham & Women's Hospital Synthetic antigens for cd1-restricted immune responses
US20030153514A1 (en) 2000-04-28 2003-08-14 Akikuni Yagita Remedies for cancer
US20020071842A1 (en) * 2000-06-05 2002-06-13 Gumperz Jenny E. Soluble CD1 compositions and uses thereof
EP1297017B1 (en) * 2000-06-19 2012-06-13 Beth Israel Deaconess Medical Center Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
AU2002327338A1 (en) 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CN1578667A (zh) 2001-11-06 2005-02-09 东方癌症治疗株式会社 抗癌组合物
WO2003105769A2 (en) * 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
WO2004094444A1 (en) 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
DK1786439T3 (da) 2004-09-03 2010-07-12 Univ Chicago Fremgangsmåder til aktivering af NKT-celler
WO2007118234A2 (en) 2006-04-07 2007-10-18 The Scripps Research Institute Modified -galactosyl ceramides for staining and stimulating natural killer t cells
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018039A1 (en) * 2001-08-22 2003-03-06 Dna Informatics Inc. Pharmaceutical ingredient for medical treatment and preventing of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Brutkiewicz, R. R. et al., Critical Reviews in Immunology, 2003, Vol. 23, pages 403-419 *
Brutkiewicz, R. R. et al., Critical Reviews in Oncology/Hematology, 2002, Vol. 41, pages 287-298 *
Singh, A. K. et al., FASEB Journal, Vol. 16, No. 5, page A1043 *
Wu, D. et al., PNAS, 2005, Vol. 102, No. 5, pages 1351-1356 *

Also Published As

Publication number Publication date
PL1848813T3 (pl) 2013-09-30
WO2006083671A2 (en) 2006-08-10
US9295722B2 (en) 2016-03-29
BRPI0607299A2 (pt) 2009-08-25
JP5053101B2 (ja) 2012-10-17
EP1848813A2 (en) 2007-10-31
US20080279894A1 (en) 2008-11-13
JP2008528608A (ja) 2008-07-31
CA2593715C (en) 2015-05-05
AU2006211485A1 (en) 2006-08-10
PT1848813E (pt) 2013-07-15
DK1848813T3 (da) 2013-07-15
ZA200706208B (en) 2008-04-30
EP1848813B1 (en) 2013-04-10
EP1848813A4 (en) 2008-07-09
ES2423005T3 (es) 2013-09-17
WO2006083671B1 (en) 2007-04-12
WO2006083671A3 (en) 2007-02-22
CA2593715A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
ZA200706208B (en) Bacterial glycolipid activation of CD1d-restricted NKT cells
Lee et al. Acemannan purified from Aloe vera induces phenotypic and functional maturation of immature dendritic cells
US11419931B2 (en) Compositions comprising bacterial strains
JP5564672B2 (ja) アジュバント及びその使用方法
Jeong et al. Invariant natural killer T cells in lung diseases
JP2010523724A (ja) α−ガラクトシルセラミド類似体およびそれらの免疫療法剤としての使用
Duramad et al. Pharmacologic expansion of donor-derived, naturally occurring CD4+ Foxp3+ regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models
Hogan et al. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide
Kamuthachad et al. Invariant natural killer T (iNKT) cells response in human melioidosis
Braedel-Ruoff et al. Legionella pneumophila mediated activation of dendritic cells involves CD14 and TLR2
Harada et al. Highly expressed dectin-1 on bone marrow-derived dendritic cells regulates the sensitivity to β-glucan in DBA/2 mice
US20090117089A1 (en) Glycolipids and analogues thereof as antigens for nk t cells
Seya et al. Two receptor theory in innate immune activation: studies on the receptors for bacillus Culmet Guillen-cell wall skeleton
US7928088B2 (en) Th1 cell differentiation accelerator
Gillard et al. Functional programming of innate immune cells in response to Bordetella pertussis infection and vaccination
Kasetthat et al. Decrease of spleen invariant natural killer T and natural killer cell numbers in Burkholderia thailandensis-infected C57BL/6 mice
KR101209416B1 (ko) 헤파린 결합 헤마글루틴（ｈｂｈａ）을 아쥬반트로 이용한 수지상 세포 암 치료제
Mierzejewska et al. De-O-acylated lipooligosaccharide of E. coli B reduces the number of metastatic foci via downregulation of myeloid cell activity
Hoebe et al. C5a Regulates NKT and NK Cell Functions in
Ohtsubo et al. Growth inhibition of tumour cells by a liposome-encapsulated, mycolic acid-containing glycolipid, trehalose 2, 3, 6'-trimycolate
KR20250121023A (ko) 강글리오사이드 NGcGM3의 합성 변형체 및 암 치료를 위한 그것의 용도
KR101290230B1 (ko) 결핵균의 Ｒｖ0652 단백질을 아쥬반트로 이용한 수지상 세포 암 치료제
Rottinghaus Pulmonary Innate Immune Mechanisms in Old Mice
Lu Acyloxyacyl Hydrolase: Studies on Its Regulation and Function in Mus Musculus
Rampuria Expansion and activation of natural killer T (NKT) cells and NKT follicular helper (NKTfh) cells in the humoral immune response to bacterial toxin

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired